Single-Incision Laparoscopic Cholecystectomy with Inflexible Laparoscopic Instruments and Laparoscopy: a Single-Center Experience
1 other identifier
observational
1,000
1 country
1
Brief Summary
Since being introduced by Mühe in 1985, laparoscopic cholecystectomy (LC) has garnered global acceptance and defined as gold standard treatment for benign gallbladder diseases (BGDs). Minimally invasive surgery technique was applied in a spectrum of surgeries including LC, namely single-incision laparoscopic cholecystectomy (SILC), initially reported by Navarra in 1997. By then this technique developed dramatically in aspects of both operation and instruments. Previous experiences with SILC across various centers have consistently demonstrated its robust safety and feasibility. Numerous clinical trials have highlighted the benefits of SILC over conventional laparoscopic cholecystectomy (CLC), particularly in terms of promoted aesthetic outcomes, reduced postoperative pain, and shorter hospital stays.However, discrepancies in postoperative complications including incisional hernias have sparked debate regarding the merits and drawbacks of SILC. Consequently, further research is urgent with larger cohorts and extended postoperative follow-up periods for a definitive assessment of SILC. In the present study LC was performed in cases from January 2023 to March 2024, aiming to compare the overall outcomes and complications between CLC and SILC. All surgical instruments and laparoscopy were introduced through a single intraumbilical incision in SILC group, allowing the resultant scar to be discreetly concealed within the reconstructed navel. Furthermore, historical implementations of SILC have predominantly utilized specialized and novel instruments. This reliance on special equipment limited the technique's applicability and benefits in settings with more rudimentary clinical facilities. The authors successfully applied conventional laparoscopic instruments and a 10mm laparoscopy with straight and inflexible properties and simplified the surgical process. Moreover, the single-incision port used were made on site from basic stuffs and materials easily obtained from operation room.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 23, 2024
CompletedFirst Submitted
Initial submission to the registry
November 25, 2024
CompletedFirst Posted
Study publicly available on registry
November 27, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 17, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 20, 2025
CompletedMarch 27, 2025
November 1, 2024
3 months
November 25, 2024
March 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Postoperative complications
Postoperative complications were graded using Clavien-Dindo classification system .
Six months postoperatively
Secondary Outcomes (2)
Postoperative quality of life
Six months postoperatively
Scar assessment
One month postoperatively
Study Arms (2)
SILC
single-incision laparoscopic cholecystectomy
CLC
conventional laparoscopic cholecystectomy
Eligibility Criteria
People with benign gallbladder diseases
You may qualify if:
- Gallbladder stone;
- Acute cholecystitis;
- Chronic cholecystitis;
- Gallbladder adenomyomatosis;
- Gallbladder polyp.
You may not qualify if:
- Combined with liver cirrhosis (Child grade B and above);
- Gallbladder gangrene perforation;
- Changes in surgical plan (conversion to laparotomy,cholangiography, bile duct exploration, bile duct injury repair, abscess clearance, multivisceral resection.);
- patients and their families do not agree with the treatment lost follow-up.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, No.88 Jiefang Road, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Daren Liu, MD, PhD
Chief Physician
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 25, 2024
First Posted
November 27, 2024
Study Start
November 23, 2024
Primary Completion
February 17, 2025
Study Completion
February 20, 2025
Last Updated
March 27, 2025
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share